AxoGen Reports Q4 Earnings Miss with Positive Revenue Growth Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy AXGN?
Source: seekingalpha
- Earnings Performance: AxoGen's Q4 non-GAAP EPS of $0.07 missed expectations by $0.03, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company reported Q4 revenue of $59.9 million, reflecting a 21.3% year-over-year increase, aligning with market expectations and demonstrating stable demand in the nerve graft market.
- Future Outlook: AxoGen anticipates at least 18% revenue growth in 2026, reaching $265.7 million, surpassing the consensus of $259.53 million, showcasing confidence in future expansion.
- Cash Flow Status: The company expects to be free cash flow positive for the full year, enhancing its financial stability, despite an 11% drop in stock price following the earnings release.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXGN
Wall Street analysts forecast AXGN stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.060
Low
39.00
Averages
39.80
High
40.00
Current: 42.060
Low
39.00
Averages
39.80
High
40.00
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TELA Bio Announces Board Refreshment Plan for Growth
- Board Refreshment Plan: TELA Bio announced a board refreshment plan post the 2026 Annual Meeting, where four current directors will step down to make way for four new directors with deep expertise in medtech commercialization, financial strategy, and corporate turnarounds, aimed at supporting the company's commercial growth and operational excellence.
- New Directors' Background: The new directors include Joseph Capper, who brings nearly 30 years of experience in medtech and successfully led BioTelemetry, Inc. through a turnaround that culminated in its $2.8 billion acquisition by Royal Philips, showcasing his capability in value creation.
- First Quarter Revenue Forecast: The company anticipates first-quarter 2026 revenue of approximately $19 million, exceeding previous guidance of $18.5 million, reflecting strong market performance and growth potential, although final results will be reported on May 12.
- Strategic Objectives: The addition of new directors will provide TELA Bio with extensive industry experience to optimize commercial organizations, enhance operational efficiency, and advance towards sustainable profitability and shareholder value creation, marking a significant shift in the company's strategic direction.
See More
Axogen Q1 2026 Earnings: Revenue Growth and Upgraded Outlook
- Revenue and Profit Performance: Axogen reported Q1 revenue of $61.5 million with a gross margin of 75.2%, demonstrating strong market execution ahead of the biologic product launch, which is expected to drive future revenue growth.
- Upgraded Outlook: The company raised its 2026 revenue expectations from at least $265.7 million to at least $270 million, increasing the growth rate to at least 20%, reflecting management's confidence in market demand and proactive business expansion.
- Insurance Coverage Progress: Cigna has extended broad coverage for the Avance nerve graft, impacting approximately 16 million members, while Elevance removed it from the experimental list, although usage is subject to management restrictions, indicating positive developments in insurance policy.
- Capital Structure and Liquidity: Axogen completed an upsized public offering raising $133.3 million, successfully retiring $69.7 million of debt, with total cash and equivalents reaching $103.6 million, providing ample funding for future growth and investments.
See More
Axogen Reports 26.6% Revenue Growth in Q1 2026
- Significant Revenue Growth: Axogen reported a revenue of $61.46 million for Q1 2026, reflecting a 26.6% increase year-over-year, indicating strong market demand for its peripheral nerve regeneration and repair technologies, thereby enhancing its competitive position in the biotech sector.
- Adjusted Net Income Positive: The company achieved an adjusted net income of $4.1 million, or $0.07 per share, compared to an adjusted net loss of $0.9 million last year, demonstrating significant improvements in cost control and operational efficiency, which may attract more investor interest.
- Upgraded Full-Year Guidance: Axogen raised its full-year revenue guidance to at least $270 million, up from the previous estimate of $265.7 million, reflecting management's confidence in future performance and potentially driving further stock price appreciation.
- Strong Cash Position: As of March 31, 2026, the company had cash and cash equivalents, restricted cash, and investments totaling $103.6 million, ensuring sufficient funding for future R&D and market expansion, thereby enhancing its financial stability.
See More
AxoGen Reports Q1 Revenue Growth of 26.6% with Positive Outlook
- Earnings Highlights: AxoGen reported a Q1 non-GAAP EPS of $0.07, aligning with expectations, while revenue reached $61.46 million, marking a 26.6% year-over-year increase and beating estimates by $3.69 million, showcasing the company's robust performance amid its biologics transition.
- Future Outlook: The company anticipates at least 20% revenue growth in 2026, equating to $270 million, with gross margins projected between 74% and 76%, which enhances investor confidence and is likely to attract further capital investment.
- Cash Flow Status: AxoGen expects to be free cash flow positive for the full year, indicating ongoing improvements in profitability and financial health, which further solidifies its market position.
- Stock Price Reaction: Following the earnings report, AxoGen's shares rose by 2%, reflecting market recognition of the company's performance and future growth potential, which may draw increased investor attention.
See More
Capricorn Fund Managers Acquires Stake in Axogen
- New Investment Insight: Capricorn Fund Managers Ltd initiated a new stake in Axogen by acquiring 687,600 shares in Q1 2026, valued at approximately $22.36 million, indicating confidence in the company despite its decade-long GAAP losses.
- Holding Proportion Analysis: This new position accounts for 3.55% of Capricorn's reportable U.S. equity assets, highlighting Axogen's significance within Capricorn's portfolio and potentially influencing future investment strategies.
- Market Performance Review: As of April 23, 2026, Axogen's shares were priced at $37.41, reflecting a 139.5% increase over the past year, significantly outperforming the S&P 500 by 107.3 percentage points, showcasing market optimism regarding its growth prospects.
- Future Outlook: Axogen anticipates at least an 18% year-over-year revenue increase for 2026 and plans to report its Q1 results on April 28, with management expecting positive free cash flow this year, further enhancing its investment appeal.
See More
Capricorn Fund Increases Stake in Axogen
- New Investment Size: Capricorn Fund acquired 687,600 shares of Axogen in Q1 2026, with an estimated transaction value of $22.36 million, indicating new interest in the company despite its decade-long losses.
- Holding Value Increase: As of March 31, 2026, the value of Axogen's stake rose to $22.78 million, reflecting the impact of both the new purchase and price changes, making it the fund's fourth-largest holding at approximately 3.55% of AUM.
- Market Outlook: Axogen expects its 2026 revenue to increase by at least 18% year-over-year, driven by FDA approval of its Avance product, which may enhance its competitiveness in the biologics market, although it still faces market challenges.
- Investment Risk Warning: While Capricorn's investment in Axogen is noteworthy, analysts point out that the company did not make the list of top investment stocks, suggesting that investors should carefully consider its long-term profitability.
See More
TELA Bio Announces Board Refreshment Plan for Growth
- Board Refreshment Plan: TELA Bio announced a board refreshment plan post the 2026 Annual Meeting, where four current directors will step down to make way for four new directors with deep expertise in medtech commercialization, financial strategy, and corporate turnarounds, aimed at supporting the company's commercial growth and operational excellence.
- New Directors' Background: The new directors include Joseph Capper, who brings nearly 30 years of experience in medtech and successfully led BioTelemetry, Inc. through a turnaround that culminated in its $2.8 billion acquisition by Royal Philips, showcasing his capability in value creation.
- First Quarter Revenue Forecast: The company anticipates first-quarter 2026 revenue of approximately $19 million, exceeding previous guidance of $18.5 million, reflecting strong market performance and growth potential, although final results will be reported on May 12.
- Strategic Objectives: The addition of new directors will provide TELA Bio with extensive industry experience to optimize commercial organizations, enhance operational efficiency, and advance towards sustainable profitability and shareholder value creation, marking a significant shift in the company's strategic direction.
See More
Axogen Q1 2026 Earnings: Revenue Growth and Upgraded Outlook
- Revenue and Profit Performance: Axogen reported Q1 revenue of $61.5 million with a gross margin of 75.2%, demonstrating strong market execution ahead of the biologic product launch, which is expected to drive future revenue growth.
- Upgraded Outlook: The company raised its 2026 revenue expectations from at least $265.7 million to at least $270 million, increasing the growth rate to at least 20%, reflecting management's confidence in market demand and proactive business expansion.
- Insurance Coverage Progress: Cigna has extended broad coverage for the Avance nerve graft, impacting approximately 16 million members, while Elevance removed it from the experimental list, although usage is subject to management restrictions, indicating positive developments in insurance policy.
- Capital Structure and Liquidity: Axogen completed an upsized public offering raising $133.3 million, successfully retiring $69.7 million of debt, with total cash and equivalents reaching $103.6 million, providing ample funding for future growth and investments.
See More
Axogen Reports 26.6% Revenue Growth in Q1 2026
- Significant Revenue Growth: Axogen reported a revenue of $61.46 million for Q1 2026, reflecting a 26.6% increase year-over-year, indicating strong market demand for its peripheral nerve regeneration and repair technologies, thereby enhancing its competitive position in the biotech sector.
- Adjusted Net Income Positive: The company achieved an adjusted net income of $4.1 million, or $0.07 per share, compared to an adjusted net loss of $0.9 million last year, demonstrating significant improvements in cost control and operational efficiency, which may attract more investor interest.
- Upgraded Full-Year Guidance: Axogen raised its full-year revenue guidance to at least $270 million, up from the previous estimate of $265.7 million, reflecting management's confidence in future performance and potentially driving further stock price appreciation.
- Strong Cash Position: As of March 31, 2026, the company had cash and cash equivalents, restricted cash, and investments totaling $103.6 million, ensuring sufficient funding for future R&D and market expansion, thereby enhancing its financial stability.
See More
AxoGen Reports Q1 Revenue Growth of 26.6% with Positive Outlook
- Earnings Highlights: AxoGen reported a Q1 non-GAAP EPS of $0.07, aligning with expectations, while revenue reached $61.46 million, marking a 26.6% year-over-year increase and beating estimates by $3.69 million, showcasing the company's robust performance amid its biologics transition.
- Future Outlook: The company anticipates at least 20% revenue growth in 2026, equating to $270 million, with gross margins projected between 74% and 76%, which enhances investor confidence and is likely to attract further capital investment.
- Cash Flow Status: AxoGen expects to be free cash flow positive for the full year, indicating ongoing improvements in profitability and financial health, which further solidifies its market position.
- Stock Price Reaction: Following the earnings report, AxoGen's shares rose by 2%, reflecting market recognition of the company's performance and future growth potential, which may draw increased investor attention.
See More
Capricorn Fund Managers Acquires Stake in Axogen
- New Investment Insight: Capricorn Fund Managers Ltd initiated a new stake in Axogen by acquiring 687,600 shares in Q1 2026, valued at approximately $22.36 million, indicating confidence in the company despite its decade-long GAAP losses.
- Holding Proportion Analysis: This new position accounts for 3.55% of Capricorn's reportable U.S. equity assets, highlighting Axogen's significance within Capricorn's portfolio and potentially influencing future investment strategies.
- Market Performance Review: As of April 23, 2026, Axogen's shares were priced at $37.41, reflecting a 139.5% increase over the past year, significantly outperforming the S&P 500 by 107.3 percentage points, showcasing market optimism regarding its growth prospects.
- Future Outlook: Axogen anticipates at least an 18% year-over-year revenue increase for 2026 and plans to report its Q1 results on April 28, with management expecting positive free cash flow this year, further enhancing its investment appeal.
See More
Capricorn Fund Increases Stake in Axogen
- New Investment Size: Capricorn Fund acquired 687,600 shares of Axogen in Q1 2026, with an estimated transaction value of $22.36 million, indicating new interest in the company despite its decade-long losses.
- Holding Value Increase: As of March 31, 2026, the value of Axogen's stake rose to $22.78 million, reflecting the impact of both the new purchase and price changes, making it the fund's fourth-largest holding at approximately 3.55% of AUM.
- Market Outlook: Axogen expects its 2026 revenue to increase by at least 18% year-over-year, driven by FDA approval of its Avance product, which may enhance its competitiveness in the biologics market, although it still faces market challenges.
- Investment Risk Warning: While Capricorn's investment in Axogen is noteworthy, analysts point out that the company did not make the list of top investment stocks, suggesting that investors should carefully consider its long-term profitability.
See More
